PMID- 10822298
OWN - NLM
STAT- MEDLINE
DCOM- 20000614
LR  - 20220310
IS  - 0969-7128 (Print)
IS  - 0969-7128 (Linking)
VI  - 7
IP  - 9
DP  - 2000 May
TI  - Intramuscular administration of E7-transfected dendritic cells generates the most 
      potent E7-specific anti-tumor immunity.
PG  - 726-33
AB  - Dendritic cells (DCs) are highly efficient antigen-presenting cells capable of 
      priming both cytotoxic and helper T cells in vivo. Recent studies have 
      demonstrated the potential use of DCs that are modified to carry tumor-specific 
      antigens in cancer vaccines. However, the optimal administration route of 
      DC-based vaccines to generate the greatest anti-tumor effect remains to be 
      determined. This study is aimed at comparing the levels of immune responses and 
      anti-tumor effect generated through different administration routes of DC-based 
      vaccination. We chose the E7 gene product of human papillomavirus (HPV) as the 
      model antigen and generated a stable DC line (designated as DC-E7) that 
      constitutively expresses the E7 gene. Among the three different routes of DC-E7 
      vaccine administration in a murine model, we found that intramuscular 
      administration generated the greatest anti-tumor immunity compared with 
      subcutaneous and intravenous routes of administration. Furthermore, intramuscular 
      administration of DC-E7 elicited the highest levels of E7-specific antibody and 
      greatest numbers of E7-specific CD4+ T helper and CD8+ T cell precursors. Our 
      results indicate that the potency of DC-based vaccines depends on the specific 
      route of administration and that intramuscular administration of E7-transfected 
      DCs generates the most potent E7-specific anti-tumor immunity.
FAU - Wang, T L
AU  - Wang TL
AD  - Department of Pathology, The Johns Hopkins Medical Institution, Baltimore, MD 
      21287, USA.
FAU - Ling, M
AU  - Ling M
FAU - Shih, I M
AU  - Shih IM
FAU - Pham, T
AU  - Pham T
FAU - Pai, S I
AU  - Pai SI
FAU - Lu, Z
AU  - Lu Z
FAU - Kurman, R J
AU  - Kurman RJ
FAU - Pardoll, D M
AU  - Pardoll DM
FAU - Wu, T C
AU  - Wu TC
LA  - eng
GR  - 5 PO1 34582-01/PHS HHS/United States
GR  - R01 CA72631-01/CA/NCI NIH HHS/United States
GR  - U19 CA72108-02/CA/NCI NIH HHS/United States
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - England
TA  - Gene Ther
JT  - Gene therapy
JID - 9421525
RN  - 0 (Cancer Vaccines)
RN  - 0 (Immunoglobulin G)
RN  - 0 (Oncogene Proteins, Viral)
RN  - 0 (Papillomavirus E7 Proteins)
RN  - 0 (oncogene protein E7, Human papillomavirus type 16)
SB  - IM
MH  - Animals
MH  - Cancer Vaccines/*administration & dosage
MH  - Dendritic Cells/*virology
MH  - Electroporation
MH  - Enzyme-Linked Immunosorbent Assay/methods
MH  - Female
MH  - Genetic Therapy/*methods
MH  - Humans
MH  - Immunoglobulin G/analysis
MH  - Immunotherapy, Active/*methods
MH  - Injections, Intramuscular
MH  - Injections, Intravenous
MH  - Injections, Subcutaneous
MH  - Mice
MH  - Mice, Inbred C57BL
MH  - Oncogene Proteins, Viral/*genetics/immunology
MH  - Papillomavirus E7 Proteins
MH  - Tumor Cells, Cultured
MH  - Uterine Cervical Neoplasms/immunology/*prevention & control
EDAT- 2000/05/24 09:00
MHDA- 2000/06/17 09:00
CRDT- 2000/05/24 09:00
PHST- 2000/05/24 09:00 [pubmed]
PHST- 2000/06/17 09:00 [medline]
PHST- 2000/05/24 09:00 [entrez]
AID - 10.1038/sj.gt.3301160 [doi]
PST - ppublish
SO  - Gene Ther. 2000 May;7(9):726-33. doi: 10.1038/sj.gt.3301160.